Hepatitis B Treatment Market: By Drug Class (Chemo Therapy, Immunosuppressant Therapy, Nucleoside Analogue), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others) and Geography  

Purchase Option

$ 4400
$ 6600
$ 8900

Hepatitis B Treatment Market size was estimated at USD 548.84 million in 2022, growing at a CAGR of 10.3% from 2023 - 2029. Hepatitis-B is also known as serum hepatitis which is an infectious disease of the liver caused by the Hepatitis-B virus (HBV). Hepatitis B is classified into two types namely, acute and chronic kidney disease (ckd) drugs. In this condition, the virus interferes with the hepatocytes and the liver becomes inflamed. Hepatitis B is commonly caused through parenteral contacts such as blood, body fluids, and sexual intercourse. The Hepatitis B virus is unable to cross the skin or mucous membranes. People with Lymph proliferative disease, Acquired Immuno Deficiency Syndrome (AIDS), and people treated with immunosuppressant drugs and hemodialysis patients easily develop an infection with the Hepatitis-B Virus. The symptoms of Hepatitis B do not develop until after a few weeks of exposure. The severity of Hepatitis may cause cirrhosis, liver failure, and hepatocellular carcinoma (HCC). A vaccine is commonly administered to protect people from the infection. Hepatitis B can be prevented by administering the hepatitis B vaccine to newborn babies, avoiding promiscuity and not having multiple sexual partners, and avoiding sharing of injections and razors can also prevent the Hepatitis B infection. Geographically, the hepatitis B treatment market is in the growing stage, as various government organizations are initiating awareness programs to prevent hepatitis B infection. An increase in the prevalence of hepatitis B infection and liver cirrhosis might fuel the hepatitis B treatment market. According to the World Health Organization, there are currently 240 million chronic carriers of the hepatitis B virus of which approximately 1525% of carriers will develop cirrhosis, hepatocellular carcinoma (HCC), or liver decompensation, and 780,000 will die each year as a result of their infection. Acquisitions and mergers, collaborations, launching of new products, increase in research and development activities, and approvals for new products from various drug regulatory bodies such as the U.S. Food and Drug Administration are some strategies followed by various companies to increase their share in the global hepatitis b treatment market. For instance, in September 2013, Roche and Inovio Pharmaceuticals collaborated on research, development, and commercialization of Inovio's highly optimized, multi-antigen DNA immunotherapies targeting hepatitis B and prostate cancer. Similarly, in July 2015, Benitec Biopharma and Biomics Biotechnologies announced that Benitec has acquired the full rights to the pre-clinical ddRNAi-based hepatitis B (HBV) therapeutic program, Hepbarna, which was previously under development as a joint venture between the two companies. In addition, Moreover, various drugs for hepatitis B treatment in the pipeline are also expected to propel the hepatitis B treatment market over the forecast period.

Hepatitis B Treatment Market Key Developments:
  • In January 2017 Gilead Sciences, Inc announced that the European Commission granted marketing authorization for Vemlidy (tenofovir alafenamide, TAF) for the treatment of chronic hepatitis B virus (HBV) infection in adults and adolescents (aged 12 years and older with body weight at least 35 kg)
  • In December 2016, Cipla received an approval from American health regulator to market Entecavir tablets used in the treatment of HBV infection

Global Hepatitis B Treatment Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

10.3%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Hepatitis B Treatment Market Dynamics

The global Hepatitis B treatment market is expected to grow at a significant CAGR due to increase in the prevalence of Hepatitis B infection. According to the World Health Organization (WHO), chronic hepatitis B virus infection occurs in majority of the infants. Rising awareness regarding hepatitis B treatment, increase in the healthcare expenditure, rise in the funding in research and development activities for hepatitis B treatment, and various pipeline products for Hepatitis B treatment might fuel the global hepatitis B treatment market over the forecast period. However, high cost of the hepatitis B treatment and medications, less effectiveness of antiviral drugs against hepatitis B infection might hamper the growth of global hepatitis B treatment market over the forecast period.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario

Global Hepatitis B Treatment Market Segmentation

By Drug Class
  • Chemo Therapy
  • Immunosuppressant
  • Nucleoside Analogue
By Route of Administration
  • Oral
  • Parenteral
  • Others
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Frequently Asked Questions

The hepatitis b treatment market size was valued at USD 548.84 million in 2022

The hepatitis b treatment market key players are: F. Hoffmann- La Roche Ltd. (Switzerland) and GlaxoSmithKline, plc. (U.K.) Bristol-Myers Squibb (U.S) Novartis AG (Switzerland) Merck and Co Inc., (U.S) Novira Therapeutics Inc. (U.S.) Johnson & Johnson Services Inc., (U.S.) Inovio Pharmaceuticals Inc. (U.S.) Benitec biopharma Ltd. (Australia) Gilead Sciences (U.S.) Cipla Inc. (India) Biomics biotechnologies (China)

The hepatitis b treatment market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.

1. Executive Summary
2. Global Hepatitis B Treatment Market Introduction 
2.1.Global Hepatitis B Treatment Market  - Taxonomy
2.2.Global Hepatitis B Treatment Market  - Definitions
2.2.1.Drug Class
2.2.2.Route of Administration
2.2.3.Distribution Channel
2.2.4.Region
3. Global Hepatitis B Treatment Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Hepatitis B Treatment Market Analysis, 2018 - 2022 and Forecast 2023 - 2029
4.1.  Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5. Global Hepatitis B Treatment Market  By Drug Class, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
5.1. Chemo Therapy
5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Immunosuppressant
5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Nucleoside Analogue
5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
6. Global Hepatitis B Treatment Market  By Route of Administration, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
6.1. Oral
6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Parenteral
6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Others
6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
7.Global Hepatitis B Treatment Market  By Distribution Channel, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
7.1. Hospital Pharmacies
7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Retail Pharmacies
7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
7.3. Others
7.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.3.3. Market Opportunity Analysis 
8.Global Hepatitis B Treatment Market  By Region, 2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9. North America Hepatitis B Treatment Market ,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
9.1. Drug Class Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Chemo Therapy
9.1.2.Immunosuppressant
9.1.3.Nucleoside Analogue
9.2.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Oral
9.2.2.Parenteral
9.2.3.Others
9.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Hospital Pharmacies
9.3.2.Retail Pharmacies
9.3.3.Others
9.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Hepatitis B Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
10.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Chemo Therapy
10.1.2.Immunosuppressant
10.1.3.Nucleoside Analogue
10.2.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Oral
10.2.2.Parenteral
10.2.3.Others
10.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Hospital Pharmacies
10.3.2.Retail Pharmacies
10.3.3.Others
10.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11. Asia Pacific (APAC) Hepatitis B Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
11.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Chemo Therapy
11.1.2.Immunosuppressant
11.1.3.Nucleoside Analogue
11.2.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Oral
11.2.2.Parenteral
11.2.3.Others
11.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Hospital Pharmacies
11.3.2.Retail Pharmacies
11.3.3.Others
11.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Hepatitis B Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
12.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Chemo Therapy
12.1.2.Immunosuppressant
12.1.3.Nucleoside Analogue
12.2.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Oral
12.2.2.Parenteral
12.2.3.Others
12.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Hospital Pharmacies
12.3.2.Retail Pharmacies
12.3.3.Others
12.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13. Latin America Hepatitis B Treatment Market,2018 - 2022 and Forecast 2023 - 2029 (Sales Value USD Million)
13.1. Drug Class Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Chemo Therapy
13.1.2.Immunosuppressant
13.1.3.Nucleoside Analogue
13.2.  Route of Administration Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Oral
13.2.2.Parenteral
13.2.3.Others
13.3.  Distribution Channel Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Hospital Pharmacies
13.3.2.Retail Pharmacies
13.3.3.Others
13.4.  Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.F. Hoffmann- La Roche Ltd. (Switzerland)
14.2.2.GlaxoSmithKline, plc. (U.K.)
14.2.3.Bristol-Myers Squibb (U.S)
14.2.4.Novartis AG (Switzerland)
14.2.5.Merck and Co Inc., (U.S)
14.2.6.Novira Therapeutics Inc. (U.S.)
14.2.7.Johnson & Johnson Services Inc., (U.S.)
14.2.8.Inovio Pharmaceuticals Inc. (U.S.)
14.2.9.Benitec biopharma Ltd. (Australia)
14.2.10.Gilead Sciences (U.S.)
14.2.11.Cipla Inc. (India)
14.2.12.Biomics biotechnologies (China)
15. Research Methodology 
16. Appendix and Abbreviations 
  • F. Hoffmann- La Roche Ltd. (Switzerland)
  • GlaxoSmithKline, plc. (U.K.)
  • Bristol-Myers Squibb (U.S)
  • Novartis AG (Switzerland)
  • Merck and Co Inc., (U.S)
  • Novira Therapeutics Inc. (U.S.)
  • Johnson & Johnson Services Inc., (U.S.)
  • Inovio Pharmaceuticals Inc. (U.S.)
  • Benitec biopharma Ltd. (Australia)
  • Gilead Sciences (U.S.)
  • Cipla Inc. (India)
  • Biomics biotechnologies (China)

Adjacent Markets